Friday, 16 October 2026European Markets

VOW Plummets 20%: Bearish Momentum Takes Hold

Loading stream...

(VIANEWS) - VOW shares have experienced a 20.74% loss on Oslo Bors Benchmark Index's decline.

About VOW

Vow ASA, a premier provider of waste management solutions, offers systems for processing and purifying wastewater, food waste, solid waste, bio sludge in Norway, France, Poland, the US, and Italy. Their operations span three sectors: Project Cruises Cruise, Aftersales Landbased. Projects Cruise specializes in advanced wastewater purification, waste management, and food waste processing systems for shipyards and owners. Aftersales provides spare parts, consumables, chemicals, as well as custom maintenance plans tailored specifically to each shipyard or owner. Landbased services offered include Biogreen's patented pyrolysis process to convert biomass, plastics and waste to energy; Safesteril's sterilisation process for food and pharmaceutical ingredients; industrial robotics solutions including waste recycling processes. Vow ASA was established in 2011 as Scanship Holding ASA; later changed to VOW ASA on 1 January 2020. They provide cruise, aquaculture and landbased industries as well as utilities with services, with partnerships including Repsol S.A, European Tyre Enterprise Ltd, GRTgaz SAS IMPROVE and Imtech Steri's Biosteam among many others. Headquartered in Lysaker Norway since then and having changed to VOW ASA on 1 January 2020

Yearly Analysis

However, VOW's low profit margins may be seen as an Achilles heel; this weakness is mitigated by its impressive return on equity. Overall, VOW appears undervalued with an excellent growth outlook; therefore it would make an excellent choice for investors interested in long-term investments that offer solid potential returns. However, investors should keep in mind that its low profit margins may pose concerns.

Technical Analysis

VOW's stock price is currently trading below both its 50-day and 200-day moving averages, indicating a bearish trend for both short- and long-term investors. Recent performance has been uneven, with intraday variation average fluctuating from 1.85% (last week) to 2.08% (last quarter). Yet its average volatility amplitude remains relatively constant; according to stochastic oscillator indicators the stock may soon experience some form of correction or pullback in near future; investors should carefully monitor VOW's performance and exercise caution when making investment decisions. Overall investors should carefully monitor VOW and exercise caution when making investments decisions.

Quarter Analysis

According to VOW's current sales growth is 7.1%. Additionally, its year-on-year quarterly revenue growth increased 12.2% year-over-year with total 831.6M for twelve trailing months indicating significant revenue expansion over this year; however revenue alone isn't enough of an indicator for profitability; expenses should also be considered when conducting analyses.

Equity Analysis

Earnings Per Share VOW currently boasts an earnings per share (EPS) value of kr0.05 in its most recent 12-month period, providing investors an indication of its profitability and ability to generate profits for shareholders. PE Ratio A company's PE Ratio of 149 indicates that investors are paying kr149 per annual earnings to purchase shares of that company's stock, giving insight into whether its share price over or undervalues potential earnings potential. VOW has generated an annualized Return on Equity of 1.13% for the twelve trailing months, providing investors with an indication of its efficiency in using its assets to generate profits. Overall, VOW appears to have a solid financial performance. While its PE Ratio may suggest overvaluation of stock, its Return on Equity indicates profitability remains relatively low - factors which should be taken into consideration by any investor when assessing VOW for potential growth and returns in the future.

More news about VOW (VOW.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com